Based on the provided content, here's a breakdown of the vulnerability information:

**CVE ID:** CVE-2022-30277

**Root Cause of Vulnerability:**
* Insufficient session expiration within BD Synapsys™ versions 4.20, 4.20 SR1, and 4.30.

**Weaknesses/Vulnerabilities Present:**
* The system does not properly terminate user sessions after a period of inactivity.

**Impact of Exploitation:**
* Extended period of time for threat actors to access sensitive information if they have already gained access.
* Unauthorized access, modification, or deletion of sensitive information, including electronic protected health information (ePHI), protected health information (PHI), and personally identifiable information (PII).
* Potential for delayed or incorrect treatment due to data modification.

**Attack Vectors:**
* Physical access to a BD Synapsys™ workstation within the customer environment.
* The attacker must have already gained access to the customer environment and have physical access to a workstation running BD Synapsys™.

**Required Attacker Capabilities/Position:**
*  Physical access to the lab or hospital network where BD Synapsys™ is deployed.
*  Low-level privileges to access the workstation.
*  User interaction is required for exploitation.

**Additional Information:**
* The vulnerability was discovered through internal testing by BD and has not been reported to be exploited in a laboratory setting.
* CVSS score: 5.7 (Medium)
* CVSS Vector: CVSS:3.1/AV:P/AC:L/PR:L/UI:R/S:U/C:H/I:H/A:N
* The vendor recommends applying compensating controls such as configuring inactivity session timeout in the operating system, physical access controls, user reminders, and ensuring standard network security policies.
* Patches are expected to remediate this vulnerability.